{"name": "Daiichi Sankyo",
 "permalink": "daiichi-sankyo",
 "crunchbase_url": "http://www.crunchbase.com/company/daiichi-sankyo",
 "homepage_url": "http://www.daiichisankyo.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "+81-3-6225-1126",
 "description": "",
 "created_at": "Wed Mar 02 04:32:04 UTC 2011",
 "updated_at": "Fri Nov 11 04:26:13 UTC 2011",
 "overview": "\u003Cp\u003EDaiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxonin for bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       23],
      "assets/images/resized/0012/4533/124533v1-max-150x150.png"],
     [[250,
       38],
      "assets/images/resized/0012/4533/124533v1-max-250x250.png"],
     [[324,
       50],
      "assets/images/resized/0012/4533/124533v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 935000000.0,
    "price_currency_code": "USD",
    "term_code": "cash_and_stock",
    "source_url": "http://www.daiichisankyo.com/news/20110301_289_E2.pdf",
    "source_description": "Plexxikon Inc. To Join Daiichi Sankyo Group",
    "acquired_year": 2011,
    "acquired_month": 2,
    "acquired_day": 28,
    "company":
     {"name": "Plexxikon",
      "permalink": "plexxikon",
      "image":
       {"available_sizes":
         [[[150,
            32],
           "assets/images/resized/0012/4532/124532v1-max-150x150.png"],
          [[224,
            49],
           "assets/images/resized/0012/4532/124532v1-max-250x250.png"],
          [[224,
            49],
           "assets/images/resized/0012/4532/124532v1-max-450x450.png"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "",
    "address2": "Chuo Ward",
    "zip_code": "",
    "city": "Tokyo",
    "state_code": null,
    "country_code": "JPN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Daiichi Sankyo makes $10M down payment on cancer drug",
    "stoned_year": 2011,
    "stoned_month": 11,
    "stoned_day": 10,
    "source_url": "http://www.fiercebiotech.com/story/daiichi-sankyo-makes-10m-down-payment-cancer-drug/2011-11-10?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Daiichi Sankyo makes $10M down payment on cancer drug",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Daiichi Sankyo",
      "permalink": "daiichi-sankyo"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}